CG Oncology Inc
CGONHealthcare|Biotechnology|USA
$75.24
+1.89 (+2.58%)
Tangible Book
$12.28
Upcoming Data Readouts (3)
Nov 2026
Est. completion
P3Non Muscle Invasive Bladder Cancer
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235n=367
Mar 2027
Est. completion
P2High-Risk Non-Muscle-Invasive Bladder Cancer
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743n=325
Jun 2030
Est. completion
P3Non Muscle Invasive Bladder Cancer
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591n=190